[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001

Phase 1

Completed

• Conditions: Dry Eye Syndromes
• Interventions: Drug: KSR-001; Drug: KSR-004; Drug: KSR-001-03; Drug: KSR-001-02

• Registration Number: NCT05017870
• Lead Sponsor: Kukje Pharma

Brief Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic characteristic of KSR-001.

Detailed Description

After single dose, safety and local tolerability were confirmed and repeated test was conducted according to the investigator's judgment.

Study Timeline

• Study Start: 2018-12-02
• Primary Completion: 2019-06-14
• Study Completion: 2020-01-15
• Status Verified: 2021-08
• Study First Submitted: 2021-08-19
• Study First Submitted QC: 2021-08-23
• Last Update Submitted: 2021-08-23
• Study First Posted: 2021-08-24
• Last Update Posted: 2021-08-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 24

Inclusion Criteria

1. Male aged between 19 and 45 years of age inclusive, at the time of signing the informed consent.
2. Body weight >= 50 kilogram and ideal body weight within the range ±20%.
3. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria

1. A subject who has symptoms of suspected acute disease at the time of screening.
2. Subjects with a history of abnormal digestive organ, kidney, respiratory, neuroendocrine, cardiovascular, hemato-oncology, urinary, musculoskeletal, immune, the nose and ears, psychiatry, stomach system.
3. A subject determined to be unsuitable as a subject through a physical examined during screening.
4. A subject who is determined to be unsuitable as a subject through an ophthalmologic examination performed during screening.
5. A subject with a history of ophthalmic surgery, trauma and chronic diseases.
6. A subject who has acute or chronic eye disease requiring the use of local eye drops at the time of screening.
7. Subjects who need to wear contact lenses during clinical trial period.
8. A subject with clinically significant allergic disease.
9. A subject with a history of drug abuse.
10. History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator contraindicates their participation.
11. The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 90 days of the biological effect of the investigational product (whichever is longer).
12. A subject who takes drugs that induce and inhibit drug metabolises such as barbital medicines within one month before the administration of clinical trial drugs.
13. A subject who donates blood to the whole blood within 60 days before the administration of a clinical trial drug or a person who donates blood to the component within 20 days before the administration of a clinical trial drug.
14. A subject who has taken a specialty drug or herbal medicine within 14 days of administration of a clinical trial drug or a general medicine or vitamin formulation within 7 days.
15. A subject who can not continually ingest caffeine or ingest caffeine-containing foods during the period from 24 hours to discharge from hospital.
16. A subject who can not drink alcohol continuously or during the period from 24 hours to discharge from hospital.
17. A subject who can not smoke excessively or quit smoking during the period from 24 hours to discharge from hospital.
18. A subject who investigator that a tester is unsuitable for participating in clinical trials due to other reasons.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
KSR-001-01	KSR-001	Participants received KSR-001-01 for 6 days.
KSR-001-04	KSR-004	Participants received KSR-001-04 for 6 days.
KSR-001-03	KSR-001-03	Participants received KSR-001-03 for 6 days.
KSR-001-02	KSR-001-02	Participants received KSR-001-02 for 6 days.

Primary Outcome Measures

Name	Time	Method
Tmax	6 days	Pharmacokinetic Characteristics
t1/2	6 days	Pharmacokinetic Characteristics
Cmax	6 days	Pharmacokinetic Characteristics

Trial Locations

Locations (1)

Kukje Pharma; 🇰🇷 Seongnam-si, Korea, Republic of